Angela Goodenough is a prominent inventor based in Morrisville, PA (US). She has made significant contributions to the field of biotechnology, particularly in the development of antibodies for therapeutic applications. With a total of 4 patents to her name, her work focuses on innovative solutions for cancer treatment.

Latest Patents

Angela's latest patents include groundbreaking inventions related to antibodies against CD73. These patents provide isolated monoclonal antibodies that bind to human Cluster of Differentiation 73 (CD73) with high affinity. The antibodies inhibit the activity of CD73 and can mediate antibody-dependent CD73 internalization. Additionally, her inventions encompass nucleic acid molecules encoding these antibodies, expression vectors, host cells, and methods for expressing the antibodies. The patents also detail immunoconjugates, bispecific molecules, and pharmaceutical compositions that utilize these antibodies. Importantly, her inventions offer methods for inhibiting the growth of tumor cells expressing CD73, presenting new avenues for treating various cancers.

Career Highlights

Angela Goodenough is currently associated with Bristol-Myers Squibb Company, where she continues to advance her research in antibody development. Her work has positioned her as a key figure in the biotechnology sector, contributing to innovative cancer therapies.

Collaborations

Throughout her career, Angela has collaborated with notable colleagues, including Nils Lonberg and Alan J Korman. These partnerships have further enhanced her research and development efforts in the field of immunotherapy.

Conclusion

Angela Goodenough's contributions to antibody research and development are paving the way for new cancer treatments. Her innovative patents and collaborations highlight her commitment to advancing medical science.

This text is generated by artificial intelligence and may not be accurate.